[Edaily Starin YUN GI BACK Reporter] The Disney+ original series “Killers’ Mall Season 2” has taken the global stage by storm immediately upon its release. Building on the artistic merit and buzz generated by Season 1, Season 2 has returned on an even grander scale, capturing the attention of viewers worldwide and raising expectations for its success. “Killers’ Mall Season 2” (Photo: The Walt Disney Company Korea) According to The Walt Disney Company Korea, “Killers’ Mall Season 2,” which released Episodes 1 and 2 on the 22nd, became the most-watched Korean original series on Disney+ worldwide on its first day of release. It also set a record for the most-watched Korean content in the Asia-Pacific (APAC) region, signaling the start of its global success. This achievement is particularly significant as it surpasses the popularity of Season 1. Season 1, released in 2024, was recognized for both its artistic merit and mass appeal—including being named one of the “Best International TV Shows of 2024” by The New York Times and one of the “Top 4 Korean Dramas of the Year” by TIME magazine—and established itself as Disney+’s flagship Korean original series. Season 2 demonstrated heightened global interest by setting viewership records that surpassed those of its predecessor from the very first day of its release. “Killers’ Mall Season 2” is a stylish action series that follows Ji-an (Kim Hye-joon), the mall’s new CEO, as she teams up with the resurrected Jin-man (Lee Dong-wook) to launch a counterattack against the global organization “Babylon.” With an expanded universe, greater scale, and even more intense action, the series promises an immersive experience that surpasses Season 1. “Killers’ Mall Season 2” will be released sequentially on Disney+ every Wednesday, with two episodes airing each week for a total of eight episodes.
The Financial Supervisory Service (FSS) has launched a surprise on-site investigation into the three major domestic credit rating agencies in connection with the series of defaults by JR GLOBAL REIT a…
SamilPharmaceutical(000520)With “Lorecivivint,” a new drug for osteoarthritis for which BioSplice holds exclusive domestic distribution rights, entering the regulatory review process in the UK followi…
BukwangPharmaceutical(003000)announced on the 11th that it was selected as a “2026 Korea’s Top Job-Creating Company” by the Ministry of Employment and Labor and received a certificate of recognition i…